HRA Pharma has established a UK subsidiary, HRA Pharma UK Ltd, based in London.
This is the company’s second subsidiary in Europe as it expands its operational presence beyond its French headquarters to support the launch of its next generation emergency contraceptive, ellaOne.
HRA Pharma UK will handle local marketing, sales and distribution of ellaOne, as well as that of its product Lysodren, indicated for the symptomatic treatment of advanced adrenal cortical carcinoma.
Tony Fraser has been named HRA Pharma UK’s General Manager. Mr Fraser has over 15 years of experience in the pharmaceutical industry, most recently as business unit director at Schering-Plough for the company’s UK-based substance misuse and virology division.
“Since the UK is Europe’s largest market for emergency contraception, we felt it was imperative to create a local entity with skilled management to support ellaOne’s upcoming launch,” said Dr Erin Gainer, CEO of HRA Pharma. “As a company who, for over a decade, has been committed to providing social programs, education and solutions to improve reproductive health as a part of our mission, we look forward to bringing ellaOne to the UK as a complementary tool in this important public health endeavour.”
HRA Pharma is a privately-held European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology.
HRA Pharma established its first European subsidiary in Germany in late 2008. Now with teams on the ground in three European countries, the company plans to pursue other key European markets in the months to come to support ellaOne, as well as to handle the local distribution of other products.